MX2022009052A - Compuestos y conjugados de estos. - Google Patents

Compuestos y conjugados de estos.

Info

Publication number
MX2022009052A
MX2022009052A MX2022009052A MX2022009052A MX2022009052A MX 2022009052 A MX2022009052 A MX 2022009052A MX 2022009052 A MX2022009052 A MX 2022009052A MX 2022009052 A MX2022009052 A MX 2022009052A MX 2022009052 A MX2022009052 A MX 2022009052A
Authority
MX
Mexico
Prior art keywords
topoisomerase inhibitor
conjugates
compounds
ligand unit
derivatives
Prior art date
Application number
MX2022009052A
Other languages
English (en)
Inventor
Philip Wilson Howard
Thais Cailleau
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2022009052A publication Critical patent/MX2022009052A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Un conjugado que comprende el siguiente derivado de un inhibidor de la topoisomerasa (A*): (ver Fórmula) A* donde Y es H o F, con un único resto conector global que une dos derivados de inhibidor de la topoisomerasa a una Unidad de Ligando, donde los derivados de inhibidor de la topoisomerasa son escindibles de la Unidad de Ligando. También se proporciona A* con la unidad conectora enlazada e intermedios para su síntesis.
MX2022009052A 2020-01-22 2021-01-21 Compuestos y conjugados de estos. MX2022009052A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062964181P 2020-01-22 2020-01-22
PCT/EP2021/051259 WO2021148500A1 (en) 2020-01-22 2021-01-21 Compounds and conjugates thereof

Publications (1)

Publication Number Publication Date
MX2022009052A true MX2022009052A (es) 2022-08-15

Family

ID=74494865

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009052A MX2022009052A (es) 2020-01-22 2021-01-21 Compuestos y conjugados de estos.

Country Status (10)

Country Link
US (1) US20230097908A1 (es)
EP (1) EP4093439A1 (es)
JP (1) JP2023511184A (es)
KR (1) KR20220130749A (es)
CN (1) CN114980934A (es)
AU (1) AU2021210570A1 (es)
BR (1) BR112022014391A2 (es)
CA (1) CA3166732A1 (es)
MX (1) MX2022009052A (es)
WO (1) WO2021148500A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109965A1 (zh) * 2021-12-16 2023-06-22 迈威(上海)生物科技股份有限公司 一种喜树碱类化合物及其偶联物
CN115160403A (zh) * 2022-07-05 2022-10-11 上海彩迩文生化科技有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
CA3052368A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors
PT1813614E (pt) 2006-01-25 2012-01-09 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
RU2505544C2 (ru) 2007-10-19 2014-01-27 Дженентек, Инк. Антитела против tenb2, сконструированные с цистеином, и конъюгаты антитело - лекарственное средство
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3538150A4 (en) 2016-11-10 2020-07-08 Medimmune, LLC ASCT2-SPECIFIC BINDING MOLECULES AND USES THEREOF
JP7244987B2 (ja) * 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
PL3946464T3 (pl) * 2019-03-29 2022-12-19 Medimmune Limited Związki i ich koniugaty

Also Published As

Publication number Publication date
AU2021210570A1 (en) 2022-09-01
JP2023511184A (ja) 2023-03-16
KR20220130749A (ko) 2022-09-27
US20230097908A1 (en) 2023-03-30
CA3166732A1 (en) 2021-07-29
EP4093439A1 (en) 2022-11-30
BR112022014391A2 (pt) 2022-09-13
CN114980934A (zh) 2022-08-30
WO2021148500A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CR20210541A (es) Compuestos y conjugados de estos
MX2022008997A (es) Compuestos y conjugados de estos.
MX2022009052A (es) Compuestos y conjugados de estos.
MX2022003740A (es) Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
WO2007113224A3 (en) Conjugation process for pnag and a carrier protein
TN2010000149A1 (en) Spiroheterocyclic pyrrolidine dione derivatives useful as pesticides
MY188455A (en) Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
MY197127A (en) Pyrrolobenzodiazepine conjugates
NZ579671A (en) Tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors
WO2008141044A3 (en) Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
CY1114922T1 (el) Κυτταροτοξικοι παραγοντες οι οποιοι περιλαμβανουν νεα παραγωγα τομαϋμυκινης και τη θεραπευτικη τους χρηση
DK1534342T3 (da) Modificerede saccharider, konjugater deraf og fremstilling deraf
WO2007106544A3 (en) Chelating conjugates having a substituted aromatic moiety and derivatives thereof
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
MX2022004875A (es) Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos.
CA3010551A1 (en) Pyrrolobenzodiazepine conjugates
WO2009043027A3 (en) Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
AUPP649498A0 (en) Organoboron derivatives and coupling thereof
WO2008042896A3 (en) Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
WO2011010084A3 (en) Cyclosporin conjugates
WO2021142258A8 (en) Macrocyclic chelates and uses thereof
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
CL2022000892A1 (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
WO2007100563A3 (en) Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates
WO2022125891A3 (en) Anti-cea immunoconjugates, and uses thereof